NASDAQ:ITCI - Intra-Cellular Therapies Stock Price, Forecast & News

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Intra-Cellular Therapies Inc (NASDAQ:ITCI) posted its quarterly earnings data on Tuesday, November, 5th. The biopharmaceutical company reported ($0.63) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.80) by $0.17. View Intra-Cellular Therapies' Earnings History.

Intra-Cellular Therapies is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Intra-Cellular Therapies.

9 brokerages have issued 1 year price targets for Intra-Cellular Therapies' shares. Their forecasts range from $16.00 to $73.00. On average, they expect Intra-Cellular Therapies' stock price to reach $37.75 in the next year. This suggests a possible upside of 57.7% from the stock's current price. View Analyst Price Targets for Intra-Cellular Therapies.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intra-Cellular Therapies.

Media stories about ITCI stock have been trending neutral this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Intra-Cellular Therapies earned a news sentiment score of 0.3 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the company's share price in the near term. View News Stories for Intra-Cellular Therapies.

Intra-Cellular Therapies saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 6,540,000 shares, a decline of 21.9% from the January 15th total of 8,370,000 shares. Based on an average daily volume of 2,790,000 shares, the days-to-cover ratio is presently 2.3 days. Currently, 14.0% of the company's stock are sold short. View Intra-Cellular Therapies' Current Options Chain.

Some companies that are related to Intra-Cellular Therapies include United Therapeutics (UTHR), BridgeBio Pharma (BBIO), Evotec (EVTCY), Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), Nektar Therapeutics (NKTR), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), HUTCHISON CHINA/S (HCM), Mirati Therapeutics (MRTX), Blueprint Medicines (BPMC), PTC Therapeutics (PTCT), Ultragenyx Pharmaceutical (RARE), SAGE Therapeutics (SAGE) and Zai Lab (ZLAB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Synergy Pharmaceuticals (SGYP), Amarin (AMRN), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Intercept Pharmaceuticals (ICPT), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), Crispr Therapeutics (CRSP), Gilead Sciences (GILD) and Clovis Oncology (CLVS).

Intra-Cellular Therapies' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (11.41%), State Street Corp (2.01%), Candriam Luxembourg S.C.A. (1.61%), Schroder Investment Management Group (1.36%), Rhenman & Partners Asset Management AB (0.90%) and DCF Advisers LLC (0.84%). Company insiders that own Intra-Cellular Therapies stock include Andrew Satlin, Christopher D Alafi, Joel S Marcus, Kimberly E Vanover, Lawrence J Hineline, Mark Neumann, Michael Halstead, Robert E Davis and Sharon Mates. View Institutional Ownership Trends for Intra-Cellular Therapies.

ITCI stock was sold by a variety of institutional investors in the last quarter, including Samlyn Capital LLC, Schroder Investment Management Group, Rhenman & Partners Asset Management AB, State Street Corp, Candriam Luxembourg S.C.A., Credit Suisse AG, Alliancebernstein L.P. and Rafferty Asset Management LLC. Company insiders that have sold Intra-Cellular Therapies company stock in the last year include Andrew Satlin, Lawrence J Hineline, Mark Neumann, Michael Halstead and Sharon Mates. View Insider Buying and Selling for Intra-Cellular Therapies.

ITCI stock was acquired by a variety of institutional investors in the last quarter, including DCF Advisers LLC, FMR LLC, First Midwest Bank Trust Division, Goldman Sachs Group Inc., UBS Group AG, Raymond James & Associates, Palo Alto Investors LP and TD Asset Management Inc.. View Insider Buying and Selling for Intra-Cellular Therapies.

Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ITCI stock can currently be purchased for approximately $23.94.

Intra-Cellular Therapies has a market capitalization of $1.33 billion and generates $250,000.00 in revenue each year. The biopharmaceutical company earns $-155,130,000.00 in net income (profit) each year or ($2.84) on an earnings per share basis. Intra-Cellular Therapies employs 73 workers across the globe.View Additional Information About Intra-Cellular Therapies.

The official website for Intra-Cellular Therapies is http://www.intracellulartherapies.com/.

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 646-440-9333 or via email at [email protected]